Komori
Nihon Trim (6788) · PolicyRestated

Allocation of retained earnings to research and development and business expansion

First written in FY2016. 4 of 7 entries say "Restated". Latest entry: FY2023.

7entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017AdvancedFY2021-Q2RestatedFY2022 – FY20232016: 120162017: 120172018: 020182019: 020192020: 320202021: 020212022: 120222023: 12023
Same theme, other companies

135 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 224 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「The Company intends to use retained earnings for future R&D activities and investments aimed at expanding the business, with the goal of achieving further growth.」

    The Company reaffirmed its policy of allocating retained earnings to investment in R&D and business expansion.
  2. FY2022RestatedAnnual report

    「The Company intends to use retained earnings for future R&D activities and investments aimed at expanding the business, with the goal of achieving further growth.」

    The Company reaffirmed its capital allocation policy of using retained earnings for investment in R&D and business expansion.
  3. FY2021-Q2AdvancedAnnual report

    「The earnings forecast for the second half includes approximately ¥300 million in upfront investment in online initiatives, which the Company has newly prioritized on the cost side. In Indonesia, the spread of COVID-19 continues, while restrictions on access to medical facilities are expected to remain in place for ステムセル研究所. Accordingly, the Company has revised its sales forecasts for both businesses conservatively.」

    The Company incorporated approximately ¥300 million of upfront investment in online initiatives into its earnings forecast, giving concrete form to its investment for future growth.
  4. FY2021-Q1RestatedAnnual report

    「The Company plans to make proactive upfront investments for future growth over the medium to long term, including investment in building new online sales channels, R&D from a medium- to long-term perspective, and preparations for M&A. This is why the Company has maintained a larger cash balance.」

    The Company reaffirmed its policy of using cash on hand, including internally generated funds, for upfront investments to support future growth, including online sales channels, R&D and preparations for M&A.
  5. FY2020RaisedAnnual report

    「We will pursue a more resilient management structure, with a view to further strengthening retained earnings so that our group can respond flexibly in emergencies such as the COVID-19 pandemic.」

    In addition to the existing policy of using retained earnings for R&D and business expansion, the Company now refers to strengthening retained earnings to prepare for emergencies.
  6. FY2017RestatedAnnual report

    「The Company intends to use retained earnings for future R&D activities and investments aimed at expanding the business, with the goal of achieving further growth.」

    The Company reaffirmed its policy of using retained earnings for investment in R&D and business expansion.
  7. FY2016First statedAnnual report

    「The Company intends to use retained earnings for future R&D activities and investments aimed at expanding the business, with the goal of achieving further growth.」

    The Company has set out a capital allocation policy of using retained earnings to invest in R&D and business expansion.
Moved together

"Full-scale rollout of the electrolysis water dialysis system" moved the same way as this thread, in the same document, in 2 of its 7 moves.

222222★123456
  1. ★This thread
  2. 1Full-scale rollout of the electrolysis water dialysis system2×
  3. 2Improving Water Purifier Cartridge Replacement Rates2×
  4. 3Storage, research and provision to medical institutions of cord blood-derived stem cells2×
  5. 4Clinical Research Support Using a License to Manufacture Specified Cell-Processed Products2×
  6. 5Share Repurchases as an Agile Capital Policy2×
  7. 6Perinatal Tissue-Derived Mesenchymal Stem Cell Business2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Nihon Trim yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.